Table 2 Additional contribution of positive 14-3-3η to identify rheumatoid arthritis amongst patients with early inflammatory arthritis
1987+/2010+ | 1987+/2010– | 1987–/2010+ | 1987–/20– | Total | Incremental benefit of 14-3-3η | |
|---|---|---|---|---|---|---|
(n = 252) number (%) | (n = 23) number (%) | (n = 29) number (%) | (n = 26) number (%) | (n = 330a) number (%) | ||
Rheumatoid factor+ | 140 (55.6) | 0 (0) | 6 (20.7) | 0 (0) | 146 (44.2) | NA |
Anti-CCP2+ | 119 (47.2) | 0 (0) | 14 (48.3) | 0 (0) | 133 (40.3) | NA |
Anti-Sa+ | 67 (26.6) | 0 (0) | 6 (20.7) | 0 (0) | 73 (22.1) | NA |
Rheumatoid factor + and/or anti-CCP2+ | 153 (60.7) | 0 (0) | 14 (48.3) | 0 (0) | 167 (50.6) | NA |
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ | 155 (61.5) | 0 (0) | 15 (51.7) | 0 (0) | 170 (51.5) | NA |
14-3-3η ≥0.19 ng/ml | 134 (50.6) | 1 (10) | 14 (43.8) | 4 (17.4) | 153 (46.4) | NA |
14-3-3η ≥0.50 ng/ml | 111 (44.0) | 0 (0) | 8 (27.6) | 0 (0) | 119 (36.1) | NA |
14-3-3η ≥ 0.19 ng/ml and/or | ||||||
Rheumatoid factor+ | 161 (63.9) | 1 (4.3) | 15 (51.7) | 4 (15.4) | 181 (54.8) | 24.0 %*** |
Anti-CCP2+ | 158 (62.7) | 1 (4.3) | 19 (65.5) | 4 (15.4) | 182 (55.2) | 36.8 %*** |
Anti-Sa+ | 144 (57.1) | 1 (4.3) | 15 (51.7) | 4 (15.4) | 164 (49.7) | 124.7 %*** |
Rheumatoid factor + and/or anti-CCP2+ | 168 (66.7) | 1 (4.3) | 19 (65.5) | 4 (15.4) | 192 (58.2) | 15.0 %*** |
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ | 170 (64.2) | 1 (10) | 19 (59.4) | 4 (17.4) | 194 (58.8) | 14.1 %*** |
14-3-3η ≥ 0.50 ng/ml and/or | ||||||
Rheumatoid factor+ | 150 (59.5) | 0 (0) | 9 (31.0) | 0 (0) | 159 (48.2) | 8.9 %*** |
Anti-CCP2+ | 147 (58.3) | 0 (0) | 15 (51.7) | 0 (0) | 162 (49.1) | 21.8 %*** |
Anti-Sa+ | 126 (50.0) | 0 (0) | 11 (37.9) | 0 (0) | 137 (41.5) | 87.7 %*** |
Rheumatoid factor + and/or anti-CCP2+ | 159 (63.1) | 0 (0) | 15 (51.7) | 0 (0) | 174 (52.7) | 4.2 %** |
Rheumatoid factor + and/or anti-CCP2+ and/or anti-Sa+ | 161 (63.9) | 0 (0) | 16 (55.2) | 0 (0) | 177 (53.6) | 4.1 %** |